Table 1.
Demographic and biological characteristics of patient cohorts.
| Normal | Median (range) | P a | ||
|---|---|---|---|---|
| range | Australian cohort | Dutch cohort | ||
| Number of patients | 61 | 35 | ||
| Ancestry | ||||
| European | 43 (70.5%) | 35 (100%) | ||
| Asian | 14 (23.0%) | 0 (0.0%) | ||
| Others | 4 (6.6%) | 0 (0.0%) | ||
| Treatment | ||||
| Carboplatin + paclitaxel | 55 (90.2%) | 35 (100%) | ||
| Carboplatin only | 6 (9.8%) | 0 (0.0%) | ||
| Pharmacokinetic sampling | ||||
| Cycle 1 | 61 (100%) | N/Ab | ||
| Cycle 3c | 7 (11.5%) | |||
| Age | 56 (19–74) | 57 (38–74) | ||
| Height (cm) | 161 (148–174) | 167 (150–179) | 0.918 | |
| Weight (kg) | 64 (36–120) | 75 (53–111) | 0.015 | |
| Total bilirubin (µmol/L) | ≤20 | 6 (2–13) | 6 (6–13) | 0.430 |
| Albumin (g/L) | 35–50 | 40 (20–49) | N/Ad | N/A |
| Alanine amino transaminase (U/L) | ≤47 | 28 (6–159) | 22 (7–55) | 0.779 |
| Aspartate amino transaminase (U/L) | ≤45 | 40 (14–242) | 24 (17–45) | 0.016 |
| Creatinine (µmol/L) | 55–105 | 60 (42–165) | 69 (45–118) | 0.002 |
| Glomerular filtration rate (mL/min) | 90–120 | 80 (22–143) | 70 (36–107) | 0.003 |
aP-values were based on independent sample median test.
bPaclitaxel sampling was performed in different treatment cycles in the Dutch cohort.
cSeven patients had carboplatin and paclitaxel sampling performed during both cycle 1 and cycle 3.
dAlbumin level results were available from only eight patients in the Dutch cohort.